文献速递头颈部肿瘤放疗中枢神经肿瘤放疗

T4期鼻咽癌调强放疗后颞叶损伤的剂量学预测因素:一项竞争风险研究

Dosimetric predictors of temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma: a competing risk study.
PubMed 文献 · Radiat Oncol · 2019-02-08

该研究回顾性分析了2008年3月至2014年12月在本中心接受全程根治性调强放疗的T4期鼻咽癌患者,采用嵌套病例对照设计,以颞叶损伤或未发生颞叶损伤的死亡为终点,用竞争风险回归模型分析预测因素。中位随访40.1个月,63例(63/506,12.5%)发生颞叶损伤,5年累积发病率为13.2%,26.7%未发生颞叶损伤而死亡。多因素分析显示D1cc和V20有统计学意义,D1cc>71.14 Gy者颞叶损伤风险为D1cc≤71.14 Gy者的7.920倍(P<0.05),V20>42.22 cc者风险亦显著升高(sHR=3.123,P<0.05)。

要点

  • T4期鼻咽癌调强放疗后5年颞叶损伤累积发病率为13.2%,26.7%未发生颞叶损伤而死亡。
  • 多因素分析显示颞叶D1cc和V20是颞叶损伤的独立预测因素,D1cc预测价值最高。
  • D1cc>71.14 Gy者颞叶损伤风险为D1cc≤71.14 Gy者的7.920倍(P<0.05)。

核心结论

  • 颞叶D1cc和V20可预测T4期鼻咽癌调强放疗后的颞叶损伤。
  • 作者认为应将D1cc和V20分别作为颞叶剂量约束的第一和第二优先考量。
  • D1cc≤71.14 Gy和V20≤42.22 cc可作为减少调强放疗计划中颞叶损伤的有用剂量体积约束,且不明显影响肿瘤覆盖。

研究设计与样本

  • 回顾性分析2008年3月至2014年12月在本中心接受全程根治性调强放疗的T4期鼻咽癌患者。
  • 采用嵌套病例对照设计,病例为随访期间经MRI诊断的颞叶损伤患者,对照为无颞叶损伤患者,按性别、诊断时年龄、颅内侵犯和随访时间1:1匹配。
  • 终点为至颞叶损伤或未发生颞叶损伤的死亡时间,分析累积发病率函数并进行竞争风险回归模型。

主要发现

  • 中位随访40.1个月,63例(63/506,12.5%)经MRI诊断发生颞叶损伤,期间发生136例死亡。
  • 5年颞叶损伤累积发病率为13.2%,26.7%未发生颞叶损伤而死亡。
  • 单因素分析显示所有选定的剂量学参数均与颞叶损伤发生相关。
  • 多因素分析显示D1cc和V20仍有统计学意义,基于AUC值D1cc被认为最具预测价值。
  • D1cc>71.14 Gy者较D1cc≤71.14 Gy者颞叶损伤风险增加7.920倍(P<0.05);V20>42.22 cc者颞叶损伤风险显著更高(sHR=3.123,P<0.05)。

关键数值与推荐

  • D1cc>71.14 Gy者较D1cc≤71.14 Gy者颞叶损伤风险增加7.920倍(P<0.05)。
  • V20>42.22 cc者颞叶损伤风险显著更高(sHR=3.123,P<0.05)。
  • D1cc≤71.14 Gy和V20≤42.22 cc可作为减少颞叶损伤的剂量体积约束。

临床怎么用

  • 作者认为应将颞叶D1cc和V20分别作为剂量约束的第一和第二优先考量。
  • 作者认为D1cc≤71.14 Gy和V20≤42.22 cc可作为调强放疗计划中有用的剂量体积约束,以减少颞叶损伤发生且不明显影响肿瘤覆盖。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with T4 nasopharyngeal carcinoma (NPC), death may occur prior to the occurrence of temporal lobe injury (TLI). Because such competing risk death precludes the occurrence of TLI and thus the competing risk analysis should be applied to TLI research. The aim was to investigate the incidence and predictive factors of TLI after intensity-modulated radiotherapy (IMRT) among T4 NPC patients. METHODS: From March 2008 to December 2014, T4 NPC patients treated with full-course radical IMRT at our center were reviewed retrospectively. A nested case-control study was designed for this cohort of patients. The cases were patients with TLI diagnosed by MRI during the follow-up period, and the controls were patients without TLI after IMRT matched 1:1 to each case by gender, age at diagnosis, intercranial involvement, and follow-up time. The end point was time to TLI or death without prior TLI. We analyzed the cumulative incidence function (CIF) and performed a competing risk regression model to identify the predictors of TLI. RESULTS: With a median follow-up of 40.1 months, 63 patients (63/506, 12.5%) developed TLI as diagnosed by MRI, and 136 deaths occurred during the period. The cumulative incidence of TLI at 5 years was 13.2%, while 26.7% died without prior TLI. The univariate analysis showed that all selected dosimetric parameters were associated with the occurrence of TLI. On multivariate analysis, D1cc and V20 remained statistically significant. Based on the area-under-the-curve (AUC) values, D1cc was considered the most predictive. The patients with D1cc > 71.14 Gy had a 7.920-fold increased risk of TLI compared with those with D1cc ≤71.14 Gy (P < 0.05). Similarly, V20 > 42.22 cc was found to result in a statistically significant higher risk of TLI (subdistribution hazard ratio [sHR] =3.123, P < 0.05). CONCLUSIONS: TL D1cc and V20 were predictive of TLI after IMRT for T4 NPC. They should be considered as first and second priorities of dose constraints of the TL. D1cc ≤71.14 Gy and V20 ≤ 42.22 cc could be useful dose-volume constraints for reducing the occurrence of TLI during IMRT treatment planning without obviously compromising the tumor coverage.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Huang J, Kong FF, Oei RW, et al. Dosimetric predictors of temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma: a competing risk study. Radiat Oncol. 2019. PMID: 30736809. doi:10.1186/s13014-019-1229-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。